CNSP - Company ID 0001729427
The table below shows CNS Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$13.81M | -$17.11M | -$14.14M | -$10.56M | -$13.54M | -$7.32M |
| Capital expenditure | $18.18K | $4.19K | $3.90K | $4.42K | $5.75K | $17.95K |
| Investing cash flow | -$18.18K | -$4.19K | -$3.90K | -$4.42K | -$5.75K | -$17.95K |
| Dividends paid | - | - | - | - |
CNS Pharmaceuticals, Inc. reported operating cash flow of -$13.81M for fiscal year 2025. That is up 19.3% from -$17.11M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$716.38K (FY 2018) to -$13.81M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $14.57M | $23.03M | $4.64M | $15.61M | $4.51M | $14.13M |